Avacta Group (LSE:AVCT), the clinical-stage cancer drug developer that operates as Avacta Therapeutics, has resumed trading on AIM after completing a fundraise during a Capital access window that closed on 6 October 2026. The company was seeking to raise £12.5 million through a placing and subscription, with the proceeds intended to extend its cash runway into the second quarter of 2027. The company has since published an announcement confirming the results of the placing and subscription.

What the Company Does

Avacta develops targeted cancer therapies built on its pre|CISION platform. The technology is designed to keep potent chemotherapy payloads inactive until they reach the tumour, where they are released by an enzyme found at high levels in the tumour microenvironment. The aim is to deliver more drug to cancer cells while reducing damage to healthy tissue, a concept the company has linked to the idea of a tumour selectivity index. This is regarded as an emerging battleground in the field of antibody-drug conjugates and related approaches.

Latest Developments

The company's recent fundraise was conducted using a capital access window, a mechanism under which trading in the shares was temporarily paused while the placing was arranged. Avacta's shares resumed trading on AIM after the window closed on 6 October 2026. The final amount raised and the issue price were set out in the company's results announcement, but were not confirmed at the time of writing.

On the clinical side, Avacta has announced that the US Food and Drug Administration cleared its investigational new drug application for AVA6103, allowing Clinical Trials of that programme to proceed in the United States. This adds a further candidate to its pipeline alongside its lead pre|CISION programme. Earlier, the company had raised funds in separate share placings, including a fundraise of around £16 million, alongside solid clinical trial data.

Financial Picture

As a clinical-stage biotechnology company, Avacta is loss-making and relies on share funding to advance its pipeline. The latest raise was explicitly aimed at extending its cash runway into the second quarter of 2027, which indicates that further funding or partnering is likely to be needed beyond that point. The company does not pay a dividend. Repeated share raises have increased the share count over time, diluting existing shareholders.

Sector and index Context

Avacta is a constituent of the FTSE AIM All Share Index. The wider oncology market has seen solid interest in targeted drug delivery, with large pharmaceutical companies paying significant sums for antibody-drug conjugate Assets and technologies. However, funding conditions for small-cap UK biotech companies have been challenging, with many relying on discounted placings to finance clinical programmes.

Key Risks

Drug development carries a high risk of failure, and clinical trial results may not support further progression. Avacta's reliance on external funding exposes shareholders to dilution, and its cash runway is finite. Regulatory decisions, competition from better-resourced rivals and the absence of a commercial Partnership are further considerations. Share prices of small biotech companies can be highly volatile around data releases and fundraises.

What to Watch Next

Investors are likely to focus on clinical data updates from the pre|CISION programmes, progress in starting trials for AVA6103 following the FDA clearance, any partnering or licensing discussions, and the company's cash position as it approaches the period covered by its current runway.